Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)

Icli, Fikri; AKBULUT, HAKAN; Onur, Handan; Yalcin, Bulent; DEMİRKAZIK, AHMET; ÇAY ŞENLER, FİLİZ

doi:10.1016/j.breast.2010.09.002

Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)

Atıf İçin Kopyala

Icli F., AKBULUT H., Onur H., Yalcin B., DEMİRKAZIK A., ÇAY ŞENLER F.

BREAST, cilt.20, sa.2, ss.155-157, 2011 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20 Sayı: 2
Basım Tarihi: 2011
Doi Numarası: 10.1016/j.breast.2010.09.002
Dergi Adı: BREAST
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.155-157
Anahtar Kelimeler: Breast cancer, Adjuvant treatment, Cisplatin, Etoposide, Docetaxel, CHEMOTHERAPY, COMBINATION, PACLITAXEL, TRIAL
Ankara Üniversitesi Adresli: Evet

Özet

Background and objectives: Previous reports suggest that including cisplatin plus etoposide in the adjuvant treatment may improve the outcomes in patients with early breast cancer.